AIMS: Our aim was to evaluate the two-year clinical results of a new @entity3446 -eluting stent (MiStent SES) with a bioabsorbable coating designed for rapid polymer dissolution but sustained drug delivery. METHODS AND RESULTS: Major adverse @entity299 (MACE), @entity177 ( @entity177 ), @entity177 ( @entity177 ), and stent @entity715 (ST) at two-year follow-up are reported for the DESSOLVE I and II trials. In DESSOLVE I, the MiStent SES (n=29) demonstrated a 3.4% two-year MACE rate without @entity177 or @entity177 . In DESSOLVE II, the MiStent group had a 6.7% (8/120) two-year MACE rate compared to 13.3% (8/60) for Endeavor (p=0.167). @entity177 was 5.0% in the MiStent and Endeavor groups (p=1.00). @entity177 was 5.0% for MiStent versus 11.7% for Endeavor (p=0.129). No probable or definite ST was reported with the MiStent up to two years. The median duration of dual antiplatelet therapy (DAPT) in DESSOLVE I and II was 364 and 366 days, respectively. CONCLUSIONS: The MiStent SES demonstrated good long-term safety and effectiveness with low two-year MACE, @entity177 , and @entity177 rates. ClinicalTrials.gov Identifiers: NCT01247428 and NCT01294748.

Evaluation of a crystalline XXXX -eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials.

@entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity177 :: ('MESH:D051437', 'Disease') :: ['target vessel failure', 'TVF', 'TLF', 'target lesion failure'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']
@entity3446 :: (MESH:D020123,Chemical) :: ['sirolimus']
